These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 9731217)

  • 1. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts.
    Kilpatrick MW; Phylactou LA; Godfrey M; Wu CH; Wu GY; Tsipouras P
    Hum Mol Genet; 1996 Dec; 5(12):1939-44. PubMed ID: 8968747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.
    Sioud M
    Nucleic Acids Res; 1997 Jan; 25(2):333-8. PubMed ID: 9016562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hammerhead ribozyme-mediated silencing of the mutant fibrillin-1 of tight skin mouse: insight into the functional role of mutant fibrillin-1.
    Menon RP; Menon MR; Shi-Wen X; Renzoni E; Bou-Gharios G; Black CM; Abraham DJ
    Exp Cell Res; 2006 May; 312(9):1463-74. PubMed ID: 16488411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
    Tabler M; Homann M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of imperfectly paired helices I and III on the catalytic activity of hammerhead ribozymes.
    Zoumadakis M; Neubert WJ; Tabler M
    Nucleic Acids Res; 1994 Dec; 22(24):5271-8. PubMed ID: 7816616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative and quantitative analysis of FBN1 mRNA from 16 patients with Marfan Syndrome.
    Tjeldhorn L; Amundsen SS; Barøy T; Rand-Hendriksen S; Geiran O; Frengen E; Paus B
    BMC Med Genet; 2015 Dec; 16():113. PubMed ID: 26684006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors altering ribozyme-mediated cleavage of tumor necrosis factor-alpha mRNA in vitro.
    Kisich KO; Freedland SJ; Erickson KL
    Biochem Biophys Res Commun; 1997 Jul; 236(1):205-11. PubMed ID: 9223453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Length variation of helix III in a hammerhead ribozyme and its influence on cleavage activity.
    Hammann C; Martinez E; Moosbauer J; Hormes R; Tabler M
    Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):25-31. PubMed ID: 10192286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.
    Dawson PA; Marini JC
    Nucleic Acids Res; 2000 Oct; 28(20):4013-20. PubMed ID: 11024182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental and bioinformatic characterisation of the promoter region of the Marfan syndrome gene, FBN1.
    Summers KM; Bokil NJ; Baisden JM; West MJ; Sweet MJ; Raggatt LJ; Hume DA
    Genomics; 2009 Oct; 94(4):233-40. PubMed ID: 19573590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of full-length beta APP mRNA by hammerhead ribozymes.
    Denman RB
    Nucleic Acids Res; 1993 Aug; 21(17):4119-25. PubMed ID: 8371986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A helix 1-extended hairpin ribozyme exhibits altered cleavage behavior in vitro.
    Moosbauer J; Tabler M
    Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):79-87. PubMed ID: 9149843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome.
    Dietz HC; McIntosh I; Sakai LY; Corson GM; Chalberg SC; Pyeritz RE; Francomano CA
    Genomics; 1993 Aug; 17(2):468-75. PubMed ID: 8406497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 TAR as anchoring site for optimized catalytic RNAs.
    Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A
    Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A ribozyme that enhances gene suppression in tobacco protoplasts.
    Perriman R; Graf L; Gerlach WL
    Antisense Res Dev; 1993; 3(3):253-63. PubMed ID: 8286926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III.
    Denman RB; Smedman M; Kung L
    Arch Biochem Biophys; 1995 Oct; 323(1):71-8. PubMed ID: 7487076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence.
    Montgomery RA; Dietz HC
    Hum Mol Genet; 1997 Apr; 6(4):519-25. PubMed ID: 9097954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.
    Grassi G; Forlino A; Marini JC
    Nucleic Acids Res; 1997 Sep; 25(17):3451-8. PubMed ID: 9254703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity.
    Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T
    Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.